Adraxe

Adraxe is a biotechnology company focused on developing innovative therapeutic antibodies for the treatment of cancer and inflammatory diseases. The company's primary research centers on targeting the Interleukin-1 receptor accessory protein (IL1RAP), a protein overexpressed in various solid tumors and involved in inflammatory signaling pathways. By leveraging its expertise in antibody engineering, Adraxe aims to create high-affinity biologics that can effectively modulate immune responses and inhibit tumor growth. The company is currently advancing its lead programs through pre-clinical development to address significant unmet medical needs in oncology and immunology.